Immune checkpoint inhibitors (ICI) have been a recent development in HCC treatment and the IMbrave 150 trial showed that atezolizumab (anti-programmable death ligand 1 (PDL1)) and bevacizumab (anti-VEGF) are an effective treatment for HCC [119]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.